![](/img/cover-not-exists.png)
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Phillips, Andrew N, Bansi-Matharu, Loveleen, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel R, Wensing, Annemarie, Lundgren, Jens D, Pillay, Deenan, Mellors, John, Cambiano, ValentJournal:
The Lancet HIV
DOI:
10.1016/S2352-3018(19)30400-X
Date:
February, 2020
File:
PDF, 108 KB
2020